Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gains from Sales and Divestitures: 2016-2017

  • Ultragenyx Pharmaceutical's Gains from Sales and Divestitures rose 198.47% to $156,021 in Q4 2017 from the same period last year, while for Dec 2017 it was $156,021, marking a year-over-year increase of 198.47%. This contributed to the annual value of $156,021 for FY2017, which is 198.47% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Gains from Sales and Divestitures stood at $156,021 for Q4 2017, which was up 198.47% from $52,273 recorded in Q4 2016.
  • In the past 5 years, Ultragenyx Pharmaceutical's Gains from Sales and Divestitures ranged from a high of $156,021 in Q4 2017 and a low of $52,273 during Q4 2016.
  • Moreover, its 2-year median value for Gains from Sales and Divestitures was $104,147 (2016), whereas its average is $104,147.
  • Data for Ultragenyx Pharmaceutical's Gains from Sales and Divestitures shows a peak YoY surged of 198.47% (in 2017) over the last 5 years.
  • Ultragenyx Pharmaceutical's Gains from Sales and Divestitures (Quarterly) stood at $52,273 in 2016, then spiked by 198.47% to $156,021 in 2017.